Peer Review History
| Original SubmissionJune 21, 2019 |
|---|
|
PONE-D-19-17494 Awareness of disease progression: a source of bias in subjective grading of ocular complications PLOS ONE Dear Dr Cardona, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Please address all reviewers comments below, including the following issues: 1. The background of the study is not clearly described in the Introduction. How does 'bias' differ from 'variability in grading'? Bias needs to be clearly defined and its sources detailed in the Introduction. There is a recent article on philosophical bias which the authors could also refer to in their deliberations on this area (Andersen et al. eLife 2019;8:e44929. DOI: https://doi.org/10.7554/eLife.44929). This article also notes the Catalogue of Biases (https://catalogofbias.org/about/) which is useful in the context of the current study. 2. The concept of bias is not novel, but rather more appreciated within the clinical and scientific community (see point 1. above). 3. Please revise the title. The participants are not given details on disease progression, but rather images with descriptors of 'treated' and 'not treated'. The study is thus addressing the impact of awareness of treatment, . 4. Please confirm that consent from the participants was given, and also provide the IRB number in the text. 5. Please see Reviewer 2 comments regarding the statistics used in this study. These comments must be addressed. 6. All participants were students within an Optometry program, and as noted in the Discussion, this limits the real-world relevance of the study. This issue should be emphasised in the Discussion. 7. There are sections in the Discussion that do not directly relate to the current study (see Reviewer 2). Please review these and remove irrelevant sections. ============================= We would appreciate receiving your revised manuscript by Sep 20 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Michele Madigan Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We noticed you have some minor occurrence of overlapping text with the following previous publication, which needs to be addressed: Cardona, Genís, and Carme Serés. "Grading contact lens complications: the effect of knowledge on grading accuracy." Current eye research 34.12 (2009): 1074-1081. In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed. 3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If the need for consent was waived by the ethics committee, please include this information 4. We note that Figure 1 in your submission contains copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission: 1. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].” 2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: General Comments In this manuscript, the authors report on the impact of “awareness of disease progression” as a source of potential bias in the grading of ocular images. The manuscript is generally well written, with some minor comments located below. There are a few scientific questions which arise from the study design which need to be addressed by the authors for this manuscript’s data to be interpreted appropriately. 1) There is the possibility of an order effect, as the labelled images were only presented on the final session. The lack of an appropriate control group which did not have labelled images in the third session make reaching conclusive conclusions regarding the observed change difficult with this as a confound. 2) The modification of the grading scale from an Ordinal/Discreet scale to one that is a more interval based one using a vertical visual analogue scale. This is different that what the scale would be used for clinically, so discussion on the impact of this modification and thus the output data which was evaluated (on a 100 point scale rather than a 0-4 scale) needs to be discussed 3) The use of deception if used typically requires a debrief of subjects after the experiment has concluded, but no details regarding if subjects were debriefed after the study was concluded has been discussed or detailed Specific Comments Ethics Statement – Incomplete (no ethics number and type of consent has been detailed) Introduction - Line 47 – change “optometrist” to “optometrists” - Line 60 – Remove “Beside” at the beginning of this sentence Methods - How do the authors propose to deal with the confound of the order effect? The changes being seen in the grading may be due to the labelling but may also be due to the learning due to the third test scenario. This could have been alleviated with the use of a control group which did not see these labels, or by randomizing the session where the labels were presented - Deception: How were subjects debriefed as to the nature and purpose of the deceit? - What is the impact of using the vertical analogue scale in conjunction with the Efron scale? The Efron scale is an ordinal scale, but the vertical analogue scale converts this to an interval scale which defines the differences between the grades to a certain value (a distance on the scale in this instance). As such, the grading is not exactly the same as grading using simply the Efron scale would be, which only has 5 discreet choices which can be made. Reviewer #2: Comments are given in the order they occur in the manuscript: 60-62: Citations required. 65: Subjective grading of ocular complications is a complex process involving the comparison of real live images, provided by the slit-lamp…. i. Isn't grading a relatively simple process for the observer? Although the neurological processing involved is undoubtedly complex, it occurs in the background without the observer’s awareness. The whole point of grading systems is that they are simple for clinicians to use, compared to the alternatives. ii. ....comparison of real-life images, obtained using a slit lamp…… 67-72: This is a very complex, composite sentence that is difficult to understand. Can it be simplified? 79-81: What is the difference between having an advanced knowledge of contact lens complications (high intensity) and having been additionally trained in ocular pathology (specificity)? Seems that these would be the same thing. 82: ….the Brien Holden…… 92: “The aim of the present study……explore additional sources of bias….”. The Introduction is unsatisfactory because, while it discusses some aspects of using grading scales (intra- and inter- user variability, tendency to use increments etc.), it does little to explain how the outcomes might be subject to bias. Thus, the suggestion here that the aim of this study is “exploring additional sources of bias” is unconvincing. Variability and bias are different phenomena and in the context of this manuscript, the Introduction should be focused on the latter rather than the former. 92: Is the term "awareness of disease progression" the most appropriate to describe what is being assessed here? What the graders are being told is whether that eye has been treated or not. They do not know anything about how the disease is progressing, just that someone has done something. Consequently the title of the paper may be misleading and should be changed. 102-109: Please verify that informed consent was obtained from participants. Did you inform the participants that they should attempt to carry out the grading according to the scale provided and irrespective of the label on the images? This is an important factor as conscious bias may be more pronounced than unconscious bias. In general, the statistical analysis seems overly complicated to achieve the stated aims. Bland & Altman (Bland and Altman 1999) have given clear guidelines on how to investigate these issues and as these methods are being used (though without appropriate citations, please add), it isn’t obvious why additional and more convoluted analyses are necessary. For any given condition (or all conditions combined) all that is needed to test the hypothesis that treatment knowledge affects grading scores is: i. First, show that the first two repeats (R1 and R2) are unbiased, i.e. the mean difference (R1-R2), for all observers, is not significantly different from zero. ii. Second, show that the third repeat (R3) is significantly biased, by demonstrating that the mean differences (R1-R3) and/or (R2-R3) are significantly different from zero. Both i) and ii) above can be achieved by observing the 95% confidence interval for the mean differences and inspection of the scatter of points in the plots may add additional insight. It isn’t clear what extra value is offered by ANOVA, correlation, ICCs etc., so these procedures need to be clearly justified, if they are to be included. 191: Why is the precision quoted for limbal vascularization different from the other features (integer vs one decimal place)? 191-194: Can you explain what the difference is between “test-retest differences” and test-retest discrepancy”? These sound like the same thing, but as the SDs being quoted are different, presumably they are not? Is the ”average value of the test-retest differences” not the same as the “average value for the test-retest discrepancy distribution”? Some elaboration and clarification is required. 246-267: This section appears to have nothing to do with the study data or outcomes. Please consider deleting it to shorten the text. 268-289: Likewise, this section repeats information already given elsewhere in the manuscript and can be deleted. 344-351: Although this is presented as the Conclusion, most of the text does not rely on or “conclude” from data presented in the manuscript. For example, the text between lines 344 and 348 makes a series of unrelated statements about clinical practice. Please revise to ensure conclusions are relevant and meaningful. The use of the word “novel’ at lines 94 and 348 is unreasonable and should be deleted. Types of bias have always existed, it is only our awareness of them that is new. Check Ref 11: Spelling of Downie. Bland, J Martin, and Douglas G Altman. 1999. 'Measuring agreement in method comparison studies', Statistical Methods in Medical Research, 8: 135-60. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-19-17494R1 Awareness of treatment: a source of bias in subjective grading of ocular complications PLOS ONE Dear Dr Cardona, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== The authors have addressed many of the issues raised in the earlier reviews, however there arel a few issues that remain to be resolved. 1. How were the Intraclass Correlation Coefficients calculated, and are these necessary given repeats one and two were analysed; please justify the use of this analysis. 2. Please report all data with significant decimal places that relates or reflects the precision of the measurement being taken. For example, grading scales to 2 significant places does not reflect the precision of grading scales per se. 3. Please address the issue of the practical and clinical significance of the overall study findings (Reviewer 2). ============================== We would appreciate receiving your revised manuscript by Nov 29 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Michele Madigan Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) Reviewer #2: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: (No Response) Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: I thank the authors for their responses and have the following further comments. As this paper is about bias, I wonder whether ICC statistics add any useful information. I agree that establishing repeatability by comparing R1 and R2 is an important step, however aren’t the mean difference between R1 and R2 and the LOAs sufficient to do this? If the authors insist on quoting ICCs, they should specify that the correlations are being calculated between R1 and R2. (lines 173-185). Also presumably ICCs were calculated for each image? Please clarify. There is still some inconsistency in precision. LOA values have 2 decimal places as quoted and ICC values have three. Note that the point here is not that they should all be the same, but that they reflect what is reasonable to expect from the characteristics of the measurement. How precise can a subjective grading instrument really be? I am very confused by the response concerning the distinction between “test-retest differences” and “test-retest discrepancy”. You say “As we had 8 images of bulbar hyperaemia and 30 participants, to determine the first set of values (0.2 ± 1.8), we calculated the mean (session 1-session 2) of the 8 images for each participant, and then we calculated the mean and SD of this value including all participants (n=30). This gave us the mean and SD of the differences between session 1 and session 2 for each condition and all participants. Similarly, for the second set of values [±4.2 (±3.7 to ±4.7)], we obtained the mean and 95% confidence intervals of the 30 values of SD obtained from the 8 differences between session 1 and session 2.” But is it not true that, in general, the grand mean of a data set is invariant to the order in which the columns and rows are averaged? In other words, it shouldn't matter if you average first across the 8 images and then over the 30 participants, or the other way around, the mean (though not the SD) will be the same. Why then, are there two different mean values quoted here? In choosing Bland Altman plots to show the data it might help readers see the differences being reported if the same Y-axis scale were used for the treated vs untreated data. Actually, a simple bar chart might be even easier to understand (one bar each for R1, R2 and R3 treated R3 untreated). One final comment is that the quoted difference between R1 and R3 (lines 193-197) all seem to be well within the LOAs for R1 vs R2, irrespective of “treatment” bias. This could reasonably be interpreted to suggest that the typical amount of bias introduce by treatment knowledge is smaller than the normal range of variation found when making successive judgments of the same image. What does this mean for the practical significance of the findings as well as the conclusion that “…more research is needed to investigate the clinical significance.”? Is there not sufficient evidence here to conclude that the effect is unlikely to be of clinical significance? ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Awareness of treatment: a source of bias in subjective grading of ocular complications PONE-D-19-17494R2 Dear Dr. Cardona, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Michele Madigan Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-19-17494R2 Awareness of treatment: a source of bias in subjective grading of ocular complications Dear Dr. Cardona: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Michele Madigan Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .